In our study, we found that the IL-21-supplemented TCR-T showed a signature of naive-like T cells after activation and simultaneously retained its effector function against tumor cells, reflecting the unique biological effects of IL-21 in supporting T cell antitumor immunity. The gene discussed is IL21; the disease is neoplasm.